论文部分内容阅读
研究了１０例正常人和２９例急性淋巴细胞性白血病（急淋）患者外周血糖皮质激素受体高、低亲和力结合位，或（ＧＣＲＨ、ＧＣＲＬ），利用Ｒｕ３８４８６对ＧＣＲＬ进行封闭，对部分患者ＧＣＲＨ、ＧＣＲＬ在激素联合化疗前后水平的变化进行了动态观察。结果表明，正常对照组ＧＣＲＨ、ＧＣＲＬ分别为４６０８±１８８９位点／细胞和１３５２３８±８８５０９位点／细胞，两者相关良好。急淋患者ＧＣＲＨ、ＧＣＲＬ分别为６０５２±３８８８位点／细胞和１２６４０５±１０２１３３位点／细胞，经过糖皮质激素药物联合化疗后，其水平分别为３６１６±１９６２位点／细胞和１４３５９７±１１２２８９位点／细胞，ＧＣＲＨ下降明显（Ｐ＜０．０１），下降率为４０．３％；而ＧＣＲＬ化疗前后差异不显著（Ｐ＞０．０５）。提示ＧＣＲＬ在介导糖皮质激素联合化疗疗效的维持中起重要的作用。
The high and low affinity binding sites of peripheral blood glucose and corticosteroid receptors in patients with normal and 29 acute lymphocytic leukemia (ALT) were studied, or (GCRH, GCRL), and GCRL was blocked with Ru38486. The changes of levels of GCRL before and after hormone combined chemotherapy were dynamically observed. The results showed that GCRH and GCRL in the normal control group were 4608±1889 sites/cell and 135238±88509 sites/cell, respectively. The GCRH and GCRL in patients with acute leukopenia were 6052±3888 sites/cell and 126405±102133 sites/cell, respectively. After glucocorticoid drugs combined with chemotherapy, the levels were 3616±1962 sites/cell and 143597±112289 sites respectively. GCRH/cells decreased significantly (P<0.01), with a decrease rate of 40.3%. There was no significant difference between GCRL and before and after chemotherapy (P>0.05). It is suggested that GCRL plays an important role in mediating the therapeutic effect of glucocorticoid combined chemotherapy.